Author Of 1 Presentation
SEVERE ACUTE ASTHMA ACROSS EUROPEAN PICUS: A EUROPEAN SOCIETY OF PAEDIATRIC AND NEONATAL INTENSIVE CARE (ESPNIC) SURVEY
Abstract
Background
Most paediatric asthma guidelines offer evidence-based or best practice approaches to the management of asthma exacerbations but struggle with an evidence-based approach for severe acute asthma (SAA). The current practices in children with SAA who are admitted to a paediatric intensive care unit (PICU) vary greatly between PICUs worldwide.
Objectives
The aim of this study is to investigate the current management practices concerning children with SAA admitted to a PICU in Europe.
Methods
Cross-sectional electronic survey across European PICUs that admit children with SAA aged 0-18 years.
Results
Thirty-seven PICUs from 11 European countries responded to the survey. In 8 PICUs (22%) a written guideline for the management of SAA children was not available. In the majority of the PICUs (95-100%) SAA treatment consisted of nebulization with beta-agonists and anticholinergics, systemic corticosteroids and intravenous (IV) magnesium sulphate (MgSO4). In 7 PICUs (19%) a loading dose of a short-acting beta agonist was part of the SAA treatment. Variations existed mainly in the use of adjunct therapies (respiratory support and medication). An asthma severity score to assess the SAA severity was used in 18 PICUs (49%), with 8 different asthma scores used.
Conclusion
Inhaled beta-agonists and anticholinergics, combined with systemic steroids and IV MgSO4 was central in the treatment of SAA children in nearly all PICUs. Importantly, in 22% of the PICUs written guidelines were not available. Variations existed in the use of adjunct therapies and an asthma severity score. Standardizing SAA guidelines across PICUs in Europe may improve quality of care.
Presenter of 1 Presentation
SEVERE ACUTE ASTHMA ACROSS EUROPEAN PICUS: A EUROPEAN SOCIETY OF PAEDIATRIC AND NEONATAL INTENSIVE CARE (ESPNIC) SURVEY
Abstract
Background
Most paediatric asthma guidelines offer evidence-based or best practice approaches to the management of asthma exacerbations but struggle with an evidence-based approach for severe acute asthma (SAA). The current practices in children with SAA who are admitted to a paediatric intensive care unit (PICU) vary greatly between PICUs worldwide.
Objectives
The aim of this study is to investigate the current management practices concerning children with SAA admitted to a PICU in Europe.
Methods
Cross-sectional electronic survey across European PICUs that admit children with SAA aged 0-18 years.
Results
Thirty-seven PICUs from 11 European countries responded to the survey. In 8 PICUs (22%) a written guideline for the management of SAA children was not available. In the majority of the PICUs (95-100%) SAA treatment consisted of nebulization with beta-agonists and anticholinergics, systemic corticosteroids and intravenous (IV) magnesium sulphate (MgSO4). In 7 PICUs (19%) a loading dose of a short-acting beta agonist was part of the SAA treatment. Variations existed mainly in the use of adjunct therapies (respiratory support and medication). An asthma severity score to assess the SAA severity was used in 18 PICUs (49%), with 8 different asthma scores used.
Conclusion
Inhaled beta-agonists and anticholinergics, combined with systemic steroids and IV MgSO4 was central in the treatment of SAA children in nearly all PICUs. Importantly, in 22% of the PICUs written guidelines were not available. Variations existed in the use of adjunct therapies and an asthma severity score. Standardizing SAA guidelines across PICUs in Europe may improve quality of care.